The Japanese guidelines for @entity697 in @entity1 recommend classifying @entity697 by age, manifestations and local findings, and also recommend myringotomy for moderate-grade cases with severe local findings, severe-grade cases, and treatment-resistant cases. The heptavalent pneumococcal conjugate vaccine was released in Japan in February 2010. In Hiroshima City, public funding allowing free inoculation with this vaccine was initiated from January 2011, and the number of vaccinated individuals has since increased dramatically. This study investigated changes in the number of myringotomies performed to treat @entity697 during the 5-year period from January 2008 to December 2012 at two hospitals and five clinics in the Asa Area of Hiroshima City, Japan. A total of 3,165 myringotomies for @entity697 were performed. The rate of procedures per @entity1 -year performed in <5-year-old @entity1 decreased by 29.1% in 2011 and by 25.2% in 2012 compared to the mean rate performed in the 3 years prior to the introduction of public funding. A total of 895 myringotomies were performed for 1-year-old @entity1 . The rate of myringotomies per @entity1 -year performed for @entity697 in 1-year-old @entity1 decreased significantly in the 2 years after the introduction of public funding for heptavalent pneumococcal conjugate vaccine compared to all years before introduction (p<0.000001). Our results suggest a benefit of heptavalent pneumococcal conjugate vaccine for @entity697 in reducing the financial burden of myringotomy. In addition, this vaccine may help prevent @entity697 with severe @entity2172 in 1-year-old @entity1 .

Influence of Pneumococcal Conjugate Vaccine on Acute @entity2172 with Severe XXXX : A Retrospective Multicenter Study.

@entity1 :: ('9606', 'Species') :: ['children', 'infants', 'child'] @entity697 :: ('MESH:D000208', 'Disease') :: ['acute otitis media'] @entity2172 :: ('MESH:D010033', 'Disease') :: ['middle ear inflammation']
@entity2172 :: (MESH:D010033,Disease) :: ['Middle Ear Inflammation']
